TROP2 _ TACSTD2 Antibody (Antigen Affinity Purified)
- Known as:
- TROP2 _ TACSTD2 Antibody (Antigen Affinity Purified)
- Catalog number:
- 10428-RP02
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Smart Serology
- Gene target:
- TROP2 _ TACSTD2 Antibody (Antigen Affinity Purified)
Related genes to: TROP2 _ TACSTD2 Antibody (Antigen Affinity Purified)
- Gene:
- TACSTD2 NIH gene
- Name:
- tumor associated calcium signal transducer 2
- Previous symbol:
- M1S1
- Synonyms:
- TROP2, GA733-1, EGP-1
- Chromosome:
- 1p32.1
- Locus Type:
- gene with protein product
- Date approved:
- 1989-11-20
- Date modifiied:
- 2019-03-01
Related products to: TROP2 _ TACSTD2 Antibody (Antigen Affinity Purified)
Related articles to: TROP2 _ TACSTD2 Antibody (Antigen Affinity Purified)
- The aim of this multicenter retrospective cohort study was to characterize the incidence, clinical presentation, timing, severity, and management of oral toxicities (OTs) associated with TROP2-directed (datopotamab deruxtecan and sacituzumab govitecan) and HER2-directed (trastuzumab deruxtecan) antibody-drug conjugates in patients with advanced-stage cancers. - Source: PubMed
Fantozzi Paolo JSonis StephenBotticelli AndreaScagnoli SimoneVerrico MonicaBianchini GiuliaBonomo Maria VittoriaBonadonna ChiaraCasagrande MathildeBorghetti LuciaTenore GianlucaDas SankalpDiaz John PRomeo UmbertoVilla Alessandro - Salivary duct carcinoma is an aggressive salivary gland malignancy in which systemic therapy is often guided by androgen receptor and HER2 status. Treatment options are limited for HER2-negative disease after progression on androgen-deprivation therapy and chemotherapy, particularly when active central nervous system (CNS) involvement develops. - Source: PubMed
Chen Guang-LiangTan BiaoCao SufenLiu XinGuo YanjingJi Dongmei - Esophageal squamous cell carcinoma (ESCC) has a poor prognosis, and new therapeutic targets are required. Antibody-drug conjugates (ADCs) are a promising therapeutic modality that selectively delivers cytotoxic payloads to tumors via cell-surface antigens. Tumor-associated calcium signal transducer 2 (TROP2, TACSTD2) has shown therapeutic potential as an ADC target in several malignancies; however, its clinical significance in ESCC remains unclear. - Source: PubMed
Publication date: 2026/09/20
Inagaki ChiakiKawakami HisatoMitani SeiichiroIijima HiroshiMatoba RyoIto AkihikoShiraisi OsamuYasuda TakushiHayashi Hidetoshi - Clear cell odontogenic carcinoma (CCOC) and hyalinizing clear cell carcinoma (HCCC), rare head-and-neck malignancies with recurrent EWSR1::CREB family fusions, show overlapping morphologic and immunophenotypic features; no standardized systemic therapy for either exists. Given tissue constraints, the molecular relationship of CCOC and HCCC to each other and to relevant head-and-neck cancers remains incompletely defined. We used spatial transcriptomic profiling, multiplex immunofluorescence (mIF), and RNA in situ hybridization (RNA-ISH) to characterize the molecular and immune landscape of CCOC, HCCC, and relevant head-and-neck and fusion-associated comparators. Key transcriptomic findings were validated by RNA-ISH (image-based signal quantification), complemented by mIF-defined immune-cell composition, antigen-presentation features, and architecture. CCOC and HCCC demonstrated highly overlapping transcriptomic profiles; clear cell sarcoma, despite shared EWSR1::CREB family fusion contexts, remained distinct. CCOC and HCCC showed enrichment of a shared epithelial-secretory program, with ductal, luminal, and regulated secretory pathway features. IGF2, among the most enriched shared transcripts, showed strong tumor-cell associated expression. Candidate targets included: TACSTD2 (TROP2), FGFR2, FOLR1, KDR, MSLN, and MUC1. mIF profiling demonstrated low B2M and HLA-I expression, sparse lymphoid infiltration, minimal PD-L1 expression, and an overall immune-cold phenotype, consistent with impaired antigen presentation. Transcriptome-wide evidence showed CCOC and HCCC share a common molecular identity, particularly distinct from myoepithelial carcinoma and squamous cell carcinoma. Implications: This study - the most comprehensive molecular comparison to date of CCOC and HCCC, set against each other and relevant differential diagnoses - establishes a shared molecular framework that may improve diagnostic classification and guide biomarker and therapeutic development for these exceptionally rare tumors. - Source: PubMed
Publication date: 2026/09/15
Hou Helen XLi AnniePatel Bidish KAckerman Emily EBisson TomFlynn SamanthaSingh SamyuktaAhmed Afrah MDeol NavkiranRivera CamronKudo YasuseiBertolus ChloeSubarnbhesaj AjiravudhVillanueva AntonioRubio KarlaRichieri Peter MBar-Peled LironTing David TFaquin William CTroulis Maria JRivera Miguel NIafrate A John - Methotrexate (MTX) resistance limits its clinical efficacy in gestational trophoblastic neoplasia (GTN). To develop safer treatment strategies for patients of reproductive age, this study aims to investigate whether anti-trophoblast cell surface antigen 2 (Anti-Trop2) facilitates the tumor-targeted delivery of MTX-loaded liposomes, thereby enhancing drug sensitivity in chemoresistant GTN. - Source: PubMed
Publication date: 2026/09/09
Wang RongFei WeidongQin JialeZheng MengxiaWu XiaodongLi ChaoqunRao XuanZheng CaihongLu WeiguoLi Xiao